clinical trial · NCT06700343
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Relapsing-remitting Multiple Sclerosis (RRMS)Ocrelizumab (US)Ocrelizumab (EU)ABP 692
brief summary
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
started
Jan 13, 2025
primary completion
Jan 15, 2027
completion
Dec 17, 2027
last updated
May 29, 2026
official title
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol